Literature DB >> 15958614

Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues.

Yidong Fan1, Zhaoxu Liu, Xiaolei Fang, Zheng Ge, Nan Ge, Yong Jia, Peng Sun, Fenglan Lou, Magnus Björkholm, Astrid Gruber, Peter Ekman, Dawei Xu.   

Abstract

Activation of telomerase, a key event during immortalization and malignant transformation, requires expression of the telomerase reverse transcriptase (hTERT). Consistently, lack of telomerase activity and hTERT expression occurs in most normal human somatic cells. However, it has been observed that both normal and cancerous renal tissues express hTERT whereas only the latter exhibits telomerase activity. The mechanism underlying the dissociation between hTERT expression and telomerase activity is unclear. In the present study, we examined telomerase activity and alternative splicing of hTERT transcripts in renal cell carcinoma (RCC) specimens and adjacent normal tissues from 33 patients with RCC. Telomerase activity was detectable in 27 of 33 (82%) RCC samples but none in their normal counterparts. Thirty-two of 33 tumors expressed overall hTERT mRNA and 27 of them contained full-length hTERT transcripts, all with telomerase activity. Although 42% (14 of 33) of normal renal samples expressed hTERT mRNA, none of them had full-length hTERT transcripts, coinciding with lack of telomerase activity. The presence of full-length hTERT mRNA and telomerase activity was significantly associated with c-MYC induction. In tumors, absence of full-length hTERT mRNA or telomerase activity defines a subgroup of nonmetastatic, early-stage RCCs. Taken together, telomerase repression in normal renal tissues is attributed to the absence of full-length hTERT transcripts, whereas telomerase activation is achieved via induction of or switch to expression of full-length hTERT mRNA during the oncogenic process of kidneys, and associated with aggressive RCCs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958614     DOI: 10.1158/1078-0432.CCR-05-0099

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

1.  Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.

Authors:  Luciana Schultz; Alcides Chaux; Roula Albadine; Jessica Hicks; Jenny J Kim; Angelo M De Marzo; Mohamad E Allaf; Michael A Carducci; Ronald Rodriguez; Hans-Joerg Hammers; Pedram Argani; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

2.  Telomere length is related to alternative splice patterns of telomerase in thyroid tumors.

Authors:  Yongchun Wang; Alan K Meeker; Jeanne Kowalski; Hua-Ling Tsai; Helina Somervell; Christopher Heaphy; Lauren E Sangenario; Nijaguna Prasad; William H Westra; Martha A Zeiger; Christopher B Umbricht
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

3.  Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms.

Authors:  Yongchun Wang; Jeanne Kowalski; Hua-Ling Tsai; Radharani Marik; Nijaguna Prasad; Helina Somervell; Pang-Kuo Lo; Lauren E Sangenario; Lars Dyrskjot; Torben F Orntoft; William H Westra; Alan K Meeker; James R Eshleman; Christopher B Umbricht; Martha A Zeiger
Journal:  Thyroid       Date:  2008-10       Impact factor: 6.568

4.  Alternative splicing and nonsense-mediated decay regulate telomerase reverse transcriptase (TERT) expression during virus-induced lymphomagenesis in vivo.

Authors:  Souheila Amor; Sylvie Remy; Ginette Dambrine; Yves Le Vern; Denis Rasschaert; Sylvie Laurent
Journal:  BMC Cancer       Date:  2010-10-21       Impact factor: 4.430

5.  Telomere length and telomerase expression in pituitary tumors.

Authors:  C S Martins; B A Santana-Lemos; F P Saggioro; L Neder; H R Machado; A C Moreira; R T Calado; M de Castro
Journal:  J Endocrinol Invest       Date:  2015-05-08       Impact factor: 4.256

6.  Full-Length Enrich c-DNA Libraries-Clear Cell-Renal Cell Carcinoma.

Authors:  Sai-Wen Tang; Jung-Yaw Lin
Journal:  J Oncol       Date:  2012-03-20       Impact factor: 4.375

7.  Immunohistochemical detection of hTERT in urothelial lesions: a potential adjunct to urine cytology.

Authors:  Walid Khalbuss; Steve Goodison
Journal:  Cytojournal       Date:  2006-08-10       Impact factor: 2.091

8.  Nucleostemin mRNA is expressed in both normal and malignant renal tissues.

Authors:  Y Fan; Z Liu; S Zhao; F Lou; S Nilsson; P Ekman; D Xu; X Fang
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

9.  Impact of Hepatitis C Virus (HCV) infection on biomolecular markers influencing the pathogenesis of bladder cancer.

Authors:  Kamel Z Hemmaid; Amira Awadalla; Essam Elsawy; Abdel-Aziz M Hussein; Azza Abdel-Aziz; Ahmed A Shokeir; Ahmed S El-Hefnawy; Hassan Abol-Enein
Journal:  Infect Agent Cancer       Date:  2013-06-28       Impact factor: 2.965

10.  TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.

Authors:  Kun Wang; Tiantian Liu; Li Liu; Jikai Liu; Cheng Liu; Chang Wang; Nan Ge; Hongbo Ren; Keqiang Yan; Sanyuan Hu; Magnus Björkholm; Yidong Fan; Dawei Xu
Journal:  Oncotarget       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.